Verrica Pharmaceuticals heads into its third-quarter report with an awkward disconnect. Last quarter, management laid out its most convincing commercial story to date: accelerating YCANTH demand, rising margins and a financing deal that pushed the cash runway into 2028. The market has since erased roughly 35% of the stock's value, leaving shares at $3.46, far below the 200-day moving average of $5.55. The report due after the close on November 12 is a test of whether that skepticism was warranted, or whether the operating improvement simply has not been priced in.

Wall Street expects a loss of 50 cents a share on revenue of about $6.2 million. The year-over-year comparisons look ugly, with revenue projected to fall 57% from $14.3 million and earnings swinging from a 5-cent profit to a sizable loss. Those headline figures are misleading. Last quarter's decline from the prior year came entirely from the roll-off of a one-time $8 million milestone payment, and the year-ago total again sits well above anything YCANTH product sales are producing today. The more useful comparison is sequential. Consensus implies only about 5% growth from the $5.9 million reported last quarter, a modest bar given that US net product revenue climbed nearly 19% in the prior period. Management offers no formal revenue guidance, so the Street's number is the only yardstick.

The key figure is dispensed applicator units. They rose from roughly 13,700 to 15,300 to about 19,600 over three quarters, with the most recent jump of 28% more than doubling the prior quarter's growth rate. The company's commercial chief cautioned, however, that summer seasonality could slow the pace, since a pediatric skin condition like molluscum tends to see fewer office visits when school is out. A flat or slightly lower unit count would be defensible. An outright decline that wipes out much of the prior quarter's gain would undercut the claim that demand is genuinely accelerating. The $0 copay refill program for eligible commercially insured patients, launched in July, offers a partial offset and an early read on whether lowering patient cost pressure can support refill volume. Gross product margin is the other proof point. It expanded from about 82% to more than 91% over three quarters, and holding near that level would confirm the improvement reflects scale rather than a one-off.

Expenses and cash matter nearly as much. Research spending tripled year over year as the common warts program ramped, with the second pivotal COVE-3 trial dosing its first patient in June and topline data now expected in mid-2027. A consensus loss of 50 cents, slightly narrower than last quarter's 54 cents, assumes the legal settlement charge that inflated the prior period does not recur and that trial spending stays contained. Investors should also check that the cash balance aligns with the 2028 runway claim. Before the new facility, cash had fallen to $11.2 million. Only $12.5 million of the $27.5 million facility from the company's chairman is available now, with the rest tied to milestones, and the arrangement carries a 16% return catch-up. Any progress toward unlocking the delayed tranche, or early contribution from the Israel distribution agreement, would strengthen the balance sheet story.

Sentiment has turned noticeably more constructive, swinging from a bearish reading last quarter to a moderately bullish one now, even as the stock has fallen. Shares sit about 8% above the post-earnings low of $3.20, a range that has shifted sharply lower from the $5 to $8.20 band of the prior quarter. That leaves little optimism built into the price.

The central question is simple: did YCANTH demand keep growing through the seasonal lull? If units and net product revenue hold their ground while margins stay above 90%, the improving narrative from last quarter remains intact and the stock's slide looks overdone. A meaningful step back in dispensed units would suggest the acceleration was less durable than management indicated, and would shift attention back to cash burn and dependence on insider financing.